Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, ...

Baricitinib was generally well-tolerated. Acne was the most common adverse event (17.6%), followed by dyslipidemia (7.8%). Asthenia, elevated liver enzymes, and weight gain each occurred in fewer than ...

Côte St. Luc City speaks out on Chanukah massacre in Australia ...